Acadia Pharma (ACAD) Commences Phase 3 Pivotal Study of Trofinetide in Rett Syndrome
Go back to Acadia Pharma (ACAD) Commences Phase 3 Pivotal Study of Trofinetide in Rett Syndrome| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 27.58 -0.44 (1.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.02 | 52 Week High | $42.49 | |||
| Open | $27.63 | 52 Week Low | $16.64 | |||
| Day High | $28.09 | P/E | N/A | |||
| Day Low | $27.10 | EPS | $-0.42 | |||
| Volume | 1,456,470 | |||||
